129 related articles for article (PubMed ID: 10431763)
21. Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea.
Hurst JS; Bazan HE
Curr Eye Res; 1995 Sep; 14(9):769-75. PubMed ID: 8529415
[TBL] [Abstract][Full Text] [Related]
22. Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products.
Juncos LA; Ren YL; Arima S; Ito S
J Clin Invest; 1993 Apr; 91(4):1374-9. PubMed ID: 8473488
[TBL] [Abstract][Full Text] [Related]
23. Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists.
Hurst JS; Bazan HE
J Ocul Pharmacol Ther; 1995; 11(3):329-37. PubMed ID: 8590265
[TBL] [Abstract][Full Text] [Related]
24. Platelet-activating factor antagonists increase vascular reactivity in perfused rat lungs.
Haynes J; Chang SW; Morris KG; Voelkel NF
J Appl Physiol (1985); 1988 Nov; 65(5):1921-8. PubMed ID: 3209541
[TBL] [Abstract][Full Text] [Related]
25. Selective inhibition of vasoconstrictor responses by platelet-activating factor in rat kidney.
Handa RK; Strandhoy JW; Buckalew VM
Am J Physiol; 1991 Jul; 261(1 Pt 2):F108-16. PubMed ID: 1907104
[TBL] [Abstract][Full Text] [Related]
26. Platelet aggregation and vasoconstriction related to platelet cyclooxygenase and 12-lipoxygenase pathways.
Michibayashi T
J Atheroscler Thromb; 2005; 12(3):154-62. PubMed ID: 16020916
[TBL] [Abstract][Full Text] [Related]
27. Endothelium-dependent relaxant action of platelet activating factor in the rat mesenteric artery.
Chiba Y; Mikoda N; Kawasaki H; Ito K
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):68-73. PubMed ID: 2314485
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological mechanisms involved in the vasodilator effects of extracts from Echinodorus grandiflorus.
Tibiriçá E; Almeida A; Caillleaux S; Pimenta D; Kaplan MA; Lessa MA; Figueiredo MR
J Ethnopharmacol; 2007 Apr; 111(1):50-5. PubMed ID: 17150321
[TBL] [Abstract][Full Text] [Related]
29. Different classes of PAF-antagonists block norepinephrine-induced vascular escape and tachyphylaxis in the isolated rabbit kidney.
Ferreira MG; Fonteles MC
Res Commun Mol Pathol Pharmacol; 1996 Nov; 94(2):147-55. PubMed ID: 8987112
[TBL] [Abstract][Full Text] [Related]
30. Effect of platelet-activating factor on porcine pulmonary blood vessels in vitro.
Pritze S; Simmet T; Peskar BA
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):495-9. PubMed ID: 1766475
[TBL] [Abstract][Full Text] [Related]
31. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist.
Hwang SB; Li CL; Lam MH; Shen TY
Lab Invest; 1985 Jun; 52(6):617-30. PubMed ID: 3925239
[TBL] [Abstract][Full Text] [Related]
32. Platelet-activating factor and not thromboxane A2 is an important mediator of endotoxin-induced platelet aggregation in equine heparinised whole blood in vitro.
Jarvis GE; Evans RJ
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):194-8. PubMed ID: 8735817
[TBL] [Abstract][Full Text] [Related]
33. L-platelet activating factor induces changes on renal vascular resistance, vascular reactivity, and renin release in the isolated perfused rat kidney.
Schwertschlag U; Scherf H; Gerber JG; Mathias M; Nies AS
Circ Res; 1987 Apr; 60(4):534-9. PubMed ID: 3297384
[TBL] [Abstract][Full Text] [Related]
34. The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers.
Havt A; Fonteles MC; Monteiro HS
Toxicon; 2001 Dec; 39(12):1841-6. PubMed ID: 11600146
[TBL] [Abstract][Full Text] [Related]
35. Reproducible vasodilatation by platelet-activating factor in blood- and Krebs-perfused rat kidneys is albumin-dependent.
Gerkens JF
Eur J Pharmacol; 1990 Feb; 177(3):119-26. PubMed ID: 2311673
[TBL] [Abstract][Full Text] [Related]
36. Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties.
Man RY; Kinnaird AA
Br J Pharmacol; 1995 Nov; 116(5):2359-64. PubMed ID: 8581269
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary vascular reactivity: effect of PAF and PAF antagonists.
Chen CR; Voelkel NF; Chang SW
J Appl Physiol (1985); 1992 Nov; 73(5):1762-9. PubMed ID: 1474049
[TBL] [Abstract][Full Text] [Related]
38. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
Lohde C; Bahr T; Labes D; Grupe R
Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
[TBL] [Abstract][Full Text] [Related]
39. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
[TBL] [Abstract][Full Text] [Related]
40. Effects of exercise training on the vascular reactivity of the whole kidney circulation in rabbits.
De Moraes R; Gioseffi G; Nóbrega AC; Tibiriçá E
J Appl Physiol (1985); 2004 Aug; 97(2):683-8. PubMed ID: 15090484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
